
|Videos|October 7, 2020
Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder
Author(s)Gerard Sanacora, MD, PhD
Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.
Advertisement
Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference
2
PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia
3
A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval
4
A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology
5










